Century Therapeutics, Inc.

NASDAQ:IPSC

Biotechnology

Healthcare
$1.38 +0.48%

+$0.01 today

Market cap
$250.60M
Beta
1.57
P/E (TTM)
-1.8
EPS (TTM)
-$1.25
52W Low $0.44High $3.04

Volume 1.14M

Average 1.12M

IPSC Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Century Therapeutics, Inc.NASDAQ: IPSC

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$3M, compared with $109.16M a year earlier. Trailing-twelve-month gross profit was -$29.86M. Over 3 fiscal years it compounded at +164.4% a year.

Context

  • Gross profit amounted to 88.0% of revenue in FY2025, down 12.0 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$3M or moves back toward the trailing-twelve-month quarterly average of -$7.47M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3M— QoQ
Last fiscal yearDec 2025
$96.06M+1357.9% YoY
LTMMar 2026
-$29.86M-126.0% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-102.8%——
1 year+1357.9%——
3-year CAGR+164.4%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
96.06M USD
Year-over-year change
+1357.9%

Gross Profit vs competitors

How IPSC compares with its peers on the latest reported figures

  • IPSC's LTM Mar 2026 gross profit of -$29.86M is the lowest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of -126.0% is the 5th highest of 7, against a peer median of -47.0%.
  • Over three fiscal years its annual growth of +164.4% compares with a peer median of +88.9%.
IPSC Competitors Peer median
Gross Profit for IPSC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$145.11M +6.2%-2.6%96.0%
CUECue Biopharma, Inc.LTM Mar 2026$32.65M +308.6%+180.5%99.8%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.23M +6860.8%—87.2%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$0 ———
EQEquillium, Inc.LTM Mar 2026-$79K -100.3%——
OSTXOS Therapies IncorporatedLTM Mar 2026-$362.39K -17280.8%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.2M -4457.3%—360.9%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$29.86M -126.0%+164.4%—
Peer median (excluding IPSC) $0-47.0%+88.9%97.9%

Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue05.2M2.24M6.59M109.16M
Cost of Revenue4.58M00013.1M
Gross Profit(4.58M)5.2M2.24M6.59M96.06M
Gross Margin—100.0%100.0%100.0%88.0%
Research & Development75.65M97.17M92.71M107.24M95.67M
Selling, General & Admin14.65M31.86M34.71M33.16M24M
Operating Expenses90.3M139.03M148.78M144.73M111.1M
Depreciation & Amortization4.58M8.44M13.04M13.3M13.1M
EBITDA(89.92M)(121.2M)(121.21M)(111.47M)3.45M
EBITDA Margin—-2331.2%-5423.2%-1691.8%3.2%
Operating Income(94.88M)(133.83M)(146.55M)(138.14M)(15.04M)
Operating Margin—-2574.2%-6556.9%-2096.5%-13.8%
Interest Income898K2.99M12.68M13.01M7.35M
Interest Expense1.28M0540K00
Other Income / Expenses(898K)2.99M11.75M13.36M5.39M
Income Before Tax(95.78M)(130.84M)(134.79M)(124.78M)(9.65M)
Pre-Tax Margin—-2516.7%-6031.0%-1893.7%-8.8%
Income Tax Expense43K91K1.88M1.79M(68K)
Net Income(95.82M)(130.93M)(136.67M)(126.57M)(9.58M)
Net Margin—-2518.4%-6115.1%-1920.9%-8.8%
EPS (Basic)(1.74)(2.27)(2.30)(1.61)(0.11)
EPS (Diluted)(1.74)(2.27)(2.30)(1.61)(0.11)
Weighted Avg Shares55.01M57.76M59.31M78.65M86.56M
Weighted Avg Shares (Diluted)55.01M57.76M59.31M78.65M86.56M

Century Therapeutics, Inc.

NASDAQ:IPSC

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.